Executive Overview
The burgeoning smart-ring sector, once a niche corner of the wearable technology market, has transformed into a high-stakes legal battlefield. Oura Health, the Finnish-founded pioneer of the category, has launched a fresh offensive against its Bengaluru-based rival, Ultrahuman, filing a new patent infringement lawsuit in a federal court in Texas. This latest legal action marks a significant escalation, as Oura seeks to secure a permanent injunction against the sales of Ultrahuman’s flagship "Ring Pro" device in the United States.
For Oura, this move is a strategic attempt to defend its intellectual property and market dominance, which it claims is being eroded by copycat innovations. For Ultrahuman, which recently secured $70 million in funding and is backed by industry giants like Qualcomm, this lawsuit represents a significant hurdle to its international expansion plans. As both companies jockey for position in an industry projected to reach 6.3 million annual shipments by 2030, the outcome of this litigation could redefine the competitive landscape of health-focused wearable tech.
Detailed Chronology: A History of Friction
The relationship between Oura and Ultrahuman has been defined by a cycle of innovation and litigation since 2023. The tension stems from Oura’s aggressive stance on protecting its proprietary technology, which includes the physical design of its rings, internal sensor placement, and data processing capabilities.
The Initial Clash
The friction first reached a boiling point when Oura initiated legal proceedings against Ultrahuman regarding the "Ring Air." Oura sought intervention from the U.S. International Trade Commission (ITC), alleging that Ultrahuman’s flagship product infringed upon its patented technologies. The resulting ITC ruling in August 2024 served as a major victory for Oura, leading to an import ban on the Ring Air. This ban effectively froze Ultrahuman’s primary revenue stream in the U.S. market for a period.
The Redesign and Re-entry
In a swift response to the ITC ruling, Ultrahuman engineering teams pivoted to develop the "Ring Pro." By redesigning the device to ostensibly circumvent the patented elements identified in the previous legal battle, the startup aimed to reclaim its foothold in the American market. In February 2026, the Ring Pro was launched, and by March, it received a favorable ruling from U.S. Customs and Border Protection, allowing the company to resume sales in the U.S.
The New Lawsuit
The relative peace following the Customs ruling was short-lived. In late October 2026, Oura filed a new complaint in Texas, asserting that the redesigned Ring Pro continues to infringe on two specific patents—D804,471 and 12,769,363. Notably, patent 12,769,363 was issued to Oura on October 20, 2026—just 48 hours before the lawsuit was initiated. This "fresh" patent covers the intricate integration of a curved battery, circuit board, and sensor array, effectively targeting the core architecture of the Ring Pro.
Additionally, Oura has expanded the scope of its complaint by naming SVTronics, a Texas-based electronics manufacturer, as a defendant. Oura alleges that SVTronics, operating under the direction of Ultrahuman, facilitates the domestic production of these allegedly infringing devices.
Supporting Context & Market Metrics
To understand why this legal warfare is occurring, one must look at the trajectory of the wearable health-tech market.
A Growing Pie
According to market research firm IDC, the global smart-ring market is on a steep upward trajectory. Shipments are expected to grow by 12.8% this year, reaching 4.9 million units. By 2030, analysts anticipate the market will hit 6.3 million units annually. As the technology matures—moving from simple step tracking to sophisticated cardiovascular health monitoring and AI-driven insights—the value of the intellectual property behind these devices becomes immense.
Oura’s Aggressive IP Strategy
Oura’s legal campaign is not limited to Ultrahuman. The company has engaged in a wide-ranging effort to consolidate its market position by challenging numerous rivals. Legal battles have been launched against industry heavyweights and startups alike, including Samsung, RingConn, Circular, and Zepp Health.
This strategy has yielded mixed results, though often in favor of Oura. For example, RingConn and Circular opted to settle their disputes by entering into multi-year licensing agreements, agreeing to pay royalties to Oura in exchange for the right to continue selling their devices in the U.S. This sets a precedent that Oura is clearly hoping to replicate with its more aggressive competitors.
Market Stagnation and Strategic Shifts
This lawsuit arrives at a complex time for Oura. Just weeks ago, the company shelved its planned $2.2 billion IPO, citing "uncertainty in the market." With the public markets currently unreceptive to its valuation, Oura is likely prioritizing the protection of its core business assets—its patents—to maintain its competitive moat and justify its private valuation to existing investors.
Official Statements
The rhetoric between the two companies reflects the high stakes involved.
Oura’s Position:
An Oura spokesperson provided a sharp critique of Ultrahuman’s business practices: "Ultrahuman has a history of copying Oura’s innovations, as demonstrated by the 2025 ITC ruling against the company. Ultrahuman introduced a redesigned ring but failed to address continued infringement of Oura’s patents, seeking instead to capitalize on our innovation and the market leadership we have built."
Oura maintains that the Customs ruling that permitted the Ring Pro’s entry was limited in scope and did not address the new, broader patent claims now being asserted in federal court.
Ultrahuman’s Rebuttal:
Mohit Kumar, the co-founder and CEO of Ultrahuman, remains defiant. In a statement to TechCrunch, he characterized the lawsuit as an opportunistic move by a dominant player: "Oura has now chosen to assert different patents, including one that issued just two days before this lawsuit was filed. We will address these claims through the appropriate legal process and will defend our position vigorously. There is no court order affecting Ring Pro, and it remains available to customers in the U.S."
Future Outlook: The Path Ahead
The resolution of this case will likely hinge on the interpretation of the two patents in question. Oura’s strategy of "patent layering"—obtaining new patents that specifically cover the design features of their rivals’ latest products—is a sophisticated tactic that forces defendants into a costly and time-consuming legal loop.
Implications for Ultrahuman
For Ultrahuman, the next few months will be critical. Having recently raised $70 million from Qualcomm Ventures and Labcorp, the company has the financial resources to mount a robust defense. Furthermore, their ongoing collaboration with Qualcomm to develop a "smart ring as a computer"—an iteration that would shift software processing from the smartphone to the ring itself—suggests that Ultrahuman is looking beyond the current design disputes. However, if the Texas court grants a preliminary or permanent injunction, Ultrahuman’s ability to generate revenue in the world’s most lucrative wearable market will be severely hampered.
The Broader Wearable Ecosystem
This legal clash highlights a systemic issue in the hardware startup space: the "patent trap." As the smart-ring category moves toward mainstream adoption, the barrier to entry is being raised by the aggressive intellectual property portfolios of incumbents.
While Oura views these lawsuits as a necessary defense of its hard-earned R&D, critics might argue that such litigation stifles innovation and limits consumer choice. As the industry moves toward AI-integrated wearables and more complex health diagnostics, the legal landscape will likely remain just as chaotic as the technological one.
For the time being, the "Ring War" is far from over. Consumers, meanwhile, continue to purchase these devices, largely unaware that each ring on their finger represents a front in a multi-million-dollar battle for the future of wearable health. As the court proceedings in Texas commence, the tech world will be watching closely to see whether the judiciary will uphold Oura’s expansive patent claims or grant the growing cohort of startups the breathing room needed to innovate.
